Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

Unless you were sleeping under a rock, you are aware of the coordinated attacks on Iran’s nuclear facilities by Israel and the United States.

July 11, 2025

Vol.51 No.27

By Robert Peter Gale

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.

House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

Over 20 scientists whose grants have been canceled by the Trump administration presented posters on their now-terminated work at “The Things We’ll Never Know: A Science Fair of Canceled Grants.”

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing

Personalis Inc. and Tempus AI Inc. have expanded and extended their strategic collaboration, adding a new indication, colorectal cancer, to the existing, exclusive commercialization agreement.

July 11, 2025

Vol.51 No.27

Clinical

She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research

Don’t try to convince Col. Susan Fondy that lymphedema doesn’t merit interest from medical researchers.

As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures

We recently had the privilege of contributing to a CBS Sunday Morning story on the ongoing crisis in the federal support for research in general and cancer research in particular.

July 03, 2025

Vol.51 No.26

By George J. Weiner and Elizabeth M. Jaffee

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

YOU MAY BE INTERESTED IN

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing

She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research

As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures

Renew today!

Subscriber content

Never miss an issue!

Login

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

YOU MAY BE INTERESTED IN

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing

She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research

As cancer scientists, we must change how we engage with the public on the impact of NIH cutsWhat the scientific method obscures

Never miss an issue!

Login

As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures